The New Mexico Medical Cannabis Program’s Medical Advisory Board voted to add Alzheimer’s Disease to the list of medical conditions eligible for the Medical Cannabis Program. The Secretary of Health will have the final decision.
If approved by the Department of Health, New Mexico would join 13 other states where patients can access medical cannabis for Alzheimer’s disease and all other types of Neurodegenerative dementia.
Alzheimer’s disease, similar to many of the conditions presently included in New Mexico’s Compassionate Use Act, is a neurologic disease and has no known cure. Existing medications provide only temporary relief, without stopping the progression of the disease.
Peer reviewed studies suggest that medical cannabis may improve symptoms related to Alzheimer’s disease and support the pharmacological and physiological benefits seen in the use of cannabinoid compounds and whole plant medicine on general symptoms of neurodegeneration.
Professor Gary Wenk, of Ohio State University, whose research focuses on chronic brain inflammation and Alzheimer’s began studying cannabis compounds after other pharmaceuticals he studied “consistently failed to reduce inflammation in the brain.” Wenk’s animal study results show cannabis to be “the most potent brain anti-inflammatory available.”
Read Full Story On: drugpolicy